JP2019535807A5 - - Google Patents

Download PDF

Info

Publication number
JP2019535807A5
JP2019535807A5 JP2019541679A JP2019541679A JP2019535807A5 JP 2019535807 A5 JP2019535807 A5 JP 2019535807A5 JP 2019541679 A JP2019541679 A JP 2019541679A JP 2019541679 A JP2019541679 A JP 2019541679A JP 2019535807 A5 JP2019535807 A5 JP 2019535807A5
Authority
JP
Japan
Prior art keywords
nitrogen
oxygen
sulfur
independently
heteroatoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019541679A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535807A (ja
JP7082130B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/056555 external-priority patent/WO2018071794A1/en
Publication of JP2019535807A publication Critical patent/JP2019535807A/ja
Publication of JP2019535807A5 publication Critical patent/JP2019535807A5/ja
Priority to JP2022000195A priority Critical patent/JP7498200B2/ja
Application granted granted Critical
Publication of JP7082130B2 publication Critical patent/JP7082130B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019541679A 2016-10-14 2017-10-13 Tyk2阻害剤およびその使用 Active JP7082130B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022000195A JP7498200B2 (ja) 2016-10-14 2022-01-04 Tyk2阻害剤およびその使用

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US201662408464P 2016-10-14 2016-10-14
US62/408,464 2016-10-14
US201662410327P 2016-10-19 2016-10-19
US201662410334P 2016-10-19 2016-10-19
US62/410,334 2016-10-19
US62/410,327 2016-10-19
US201662413829P 2016-10-27 2016-10-27
US62/413,829 2016-10-27
US201662415920P 2016-11-01 2016-11-01
US62/415,920 2016-11-01
US201762468767P 2017-03-08 2017-03-08
US201762468807P 2017-03-08 2017-03-08
US201762468749P 2017-03-08 2017-03-08
US62/468,807 2017-03-08
US62/468,749 2017-03-08
US62/468,767 2017-03-08
US201762546278P 2017-08-16 2017-08-16
US62/546,278 2017-08-16
PCT/US2017/056555 WO2018071794A1 (en) 2016-10-14 2017-10-13 Tyk2 inhibitors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022000195A Division JP7498200B2 (ja) 2016-10-14 2022-01-04 Tyk2阻害剤およびその使用

Publications (3)

Publication Number Publication Date
JP2019535807A JP2019535807A (ja) 2019-12-12
JP2019535807A5 true JP2019535807A5 (https=) 2020-11-19
JP7082130B2 JP7082130B2 (ja) 2022-06-07

Family

ID=61906011

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019541679A Active JP7082130B2 (ja) 2016-10-14 2017-10-13 Tyk2阻害剤およびその使用
JP2022000195A Active JP7498200B2 (ja) 2016-10-14 2022-01-04 Tyk2阻害剤およびその使用
JP2023091142A Withdrawn JP2023106606A (ja) 2016-10-14 2023-06-01 Tyk2阻害剤およびその使用
JP2025202716A Pending JP2026035684A (ja) 2016-10-14 2025-11-25 Tyk2阻害剤およびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022000195A Active JP7498200B2 (ja) 2016-10-14 2022-01-04 Tyk2阻害剤およびその使用
JP2023091142A Withdrawn JP2023106606A (ja) 2016-10-14 2023-06-01 Tyk2阻害剤およびその使用
JP2025202716A Pending JP2026035684A (ja) 2016-10-14 2025-11-25 Tyk2阻害剤およびその使用

Country Status (10)

Country Link
US (4) US10323036B2 (https=)
EP (2) EP3848370B1 (https=)
JP (4) JP7082130B2 (https=)
CN (1) CN109952303B (https=)
AU (3) AU2017342464B2 (https=)
CA (1) CA3039202A1 (https=)
ES (1) ES2930198T3 (https=)
IL (2) IL265922B2 (https=)
TW (2) TWI763722B (https=)
WO (1) WO2018071794A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3262049B1 (en) 2015-02-27 2022-07-20 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
EP4327809A3 (en) 2015-09-02 2024-04-17 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
EP3848370B1 (en) 2016-10-14 2025-05-07 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
EP3528816A4 (en) * 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
GB201617871D0 (en) * 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
JP7160824B2 (ja) 2017-03-08 2022-10-25 ニンバス ラクシュミ, インコーポレイテッド Tyk2阻害剤、使用およびその製造のための方法
KR102717819B1 (ko) 2017-07-28 2024-10-14 다케다 야쿠힌 고교 가부시키가이샤 Tyk2 억제제 및 이의 용도
AU2019234574A1 (en) 2018-03-12 2020-09-03 Abbvie Inc. Inhibitors of tyrosine kinase 2 mediated signaling
US12448374B2 (en) 2018-06-07 2025-10-21 Disarm Therapeutics, Inc. Inhibitors of SARM1
US12030875B2 (en) 2018-09-07 2024-07-09 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
JP7619951B2 (ja) 2018-10-15 2025-01-22 武田薬品工業株式会社 Tyk2阻害剤およびその使用
JP7530360B2 (ja) * 2018-11-30 2024-08-07 武田薬品工業株式会社 Tyk2阻害剤およびその使用
CN120865208A (zh) 2019-01-23 2025-10-31 武田药品工业株式会社 Tyk2抑制剂和其用途
WO2020159904A1 (en) * 2019-01-30 2020-08-06 Bristol-Myers Squibb Company Amide-disubstituted pyridine or pyridazine compounds
WO2020222773A1 (en) 2019-04-30 2020-11-05 Celgene Corporation Combination therapies comprising apremilast and tyk2 inhibitors
WO2021009568A1 (en) 2019-07-17 2021-01-21 2692372 Ontario, Inc. Benzenesulfonamide derivatives and uses thereof
WO2021048736A1 (en) * 2019-09-11 2021-03-18 Pfizer Inc. Treatment of hidradenitis with jak inhibitors
CN115003667B (zh) 2020-02-26 2025-04-15 百济神州有限公司 Tyk-2抑制剂
AU2021230289A1 (en) 2020-03-03 2022-09-29 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
WO2021237121A1 (en) * 2020-05-21 2021-11-25 Gossamer Bio Services, Inc. Substituted pyridines
IL299294A (en) * 2020-06-22 2023-02-01 Beigene Ltd tyk-2 inhibitor
WO2022083560A1 (zh) * 2020-10-19 2022-04-28 南京药石科技股份有限公司 Tyk2选择性抑制剂及其用途
GB2617477A (en) 2020-11-20 2023-10-11 2692372 Ontario Inc Benzenesulfonamide derivatives and uses thereof
WO2022136914A1 (en) * 2020-12-23 2022-06-30 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
CA3207819A1 (en) 2021-02-19 2022-08-25 Anjali Pandey Tyk2 inhibitors and uses thereof
IL305165A (en) 2021-02-19 2023-10-01 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof
US12600721B2 (en) 2021-02-19 2026-04-14 Sudo Biosciences Limited TYK2 inhibitors and uses thereof
EP4308556A4 (en) 2021-03-16 2025-02-19 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Amino heteroaryl compounds and compositions
AU2022268464B2 (en) * 2021-05-04 2025-04-17 Shanghai Zheye Biotechnology Co. Ltd. Nitrogen-containing heterocyclic pyridine compound
CN115466289A (zh) * 2021-06-11 2022-12-13 爱科诺生物医药(香港)有限公司 具有tyk2抑制活性的化合物,包含其的药物组合物,及其应用
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
JP2024534127A (ja) 2021-08-25 2024-09-18 ピク セラピューティクス, インコーポレイテッド eIF4E阻害剤及びその使用
WO2023055901A2 (en) 2021-09-30 2023-04-06 Bristol-Myers Squibb Company Methods for determining responsiveness to tyk2 inhibitors
JP2024539280A (ja) 2021-10-25 2024-10-28 カイメラ セラピューティクス, インコーポレイテッド Tyk2分解剤およびそれらの使用
WO2023116822A1 (en) * 2021-12-23 2023-06-29 Beigene, Ltd. Solid forms of a tyk2 inhibitor, method of preparation, and use thereof
WO2023220046A1 (en) * 2022-05-10 2023-11-16 Biogen Ma Inc. Tyk2 inhibitors
WO2023248010A2 (en) 2022-06-23 2023-12-28 Synovo Gmbh Targeted modulators of jak3 for treatment of inflammatory and autoimmune diseases
US20240124450A1 (en) 2022-09-21 2024-04-18 Pfizer Inc. Novel SIK Inhibitors
CN115819429A (zh) * 2022-12-13 2023-03-21 成都睿智化学研究有限公司 一种5-氯-2,3-二氢呋喃[2,3-c]吡啶的合成方法
WO2024193689A1 (zh) * 2023-03-23 2024-09-26 广东东阳光药业股份有限公司 吡啶并吡咯衍生物及其在药物中的用途
WO2024211708A1 (en) * 2023-04-06 2024-10-10 Myrobalan Therapeutics, Inc. Tyk2 inhibitors for treatment of glaucoma
WO2024217523A1 (en) * 2023-04-20 2024-10-24 Myrobalan Therapeutics Nanjing Co. Ltd Selective tky2 inhibitors and uses thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
GB599891A (en) * 1944-11-17 1948-03-23 Gen Aniline & Film Corp 1-substituted-2,5-diketo-7-methyl-pyrimido-pyrazoles and process of preparing the same
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
EP1382339B1 (en) 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP1389617B1 (en) 2001-04-27 2007-01-03 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
US20050043315A1 (en) * 2002-01-02 2005-02-24 Hideo Tsutsumi Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2004019973A1 (en) 2002-08-14 2004-03-11 Atugen Ag Use of protein kinase n beta
KR20070087266A (ko) 2003-04-03 2007-08-28 세마포르 파머슈티컬즈, 아이엔씨. 피아이-3 키나아제 억제제 프로드러그
CN1832939B (zh) 2003-05-30 2010-04-28 杰明X医药品加拿大公司 用于治疗癌症或病毒病的三杂环化合物、组合物和方法
US7173015B2 (en) 2003-07-03 2007-02-06 The Trustees Of The University Of Pennsylvania Inhibition of Syk kinase expression
CN1950389B (zh) 2004-03-04 2011-01-19 橘生药品工业株式会社 含氮稠环衍生物,含该衍生物的药物组合物,和其作为药物的用途
SI2612862T1 (sl) 2004-05-13 2017-04-26 Icos Corporation Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
EP1888550B1 (en) 2005-05-12 2014-06-25 AbbVie Bahamas Ltd. Apoptosis promoters
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
BRPI0617162B8 (pt) 2005-10-07 2021-05-25 Exelixis Inc compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
CN103626742B (zh) 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
CA2637172A1 (en) * 2006-01-27 2007-08-09 Array Biopharma Inc. Pyridin-2-amine derivatives and their use as glucokinase activators
JP2009525978A (ja) * 2006-02-06 2009-07-16 アイアールエム・リミテッド・ライアビリティ・カンパニー プロテインキナーゼ阻害剤としての化合物および組成物
MX2008013578A (es) 2006-04-26 2009-03-23 Hoffmann La Roche Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
US8846704B2 (en) * 2007-01-31 2014-09-30 YM Biosciences Austraila Pty Ltd Thiopyrimidine-based compounds and uses thereof
HRP20151386T1 (hr) 2007-03-12 2016-02-26 Ym Biosciences Australia Pty Ltd Fenil aminopirimidinski spojevi i njihova primjena
EA200901133A1 (ru) * 2007-03-20 2010-04-30 Смитклайн Бичем Корпорейшн Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
GB0719644D0 (en) * 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
WO2009155156A1 (en) 2008-06-18 2009-12-23 Merck & Co., Inc. Inhibitors of janus kinases
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
AU2011272862A1 (en) * 2010-06-30 2013-01-10 Amgen Inc. Heterocyclic compounds and their use as inhibitors of PI3K activity
AU2011328237A1 (en) * 2010-11-09 2013-05-23 Cellzome Limited Pyridine compounds and aza analogues thereof as TYK2 inhibitors
US9033542B2 (en) * 2010-11-16 2015-05-19 Dialight Corporation LED luminaire utilizing an extended and non-metallic enclosure
MX2013005445A (es) * 2010-11-19 2013-07-29 Hoffmann La Roche Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2).
EP2802576B1 (en) * 2012-01-13 2018-06-27 Bristol-Myers Squibb Company Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
WO2013106614A1 (en) * 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
CN104254533B (zh) * 2012-01-13 2017-09-08 百时美施贵宝公司 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物
MY194668A (en) 2012-11-08 2022-12-12 Bristol Myers Squibb Co Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn() responses
US9315494B2 (en) 2012-11-08 2016-04-19 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
AU2014211856C1 (en) * 2013-02-02 2018-04-12 Centaurus Biopharma Co., Ltd. Substituted 2-aminopyridine protein kinase inhibitor
WO2014210354A1 (en) * 2013-06-28 2014-12-31 Genentech, Inc. Azaindazole compounds as inhibitors of t790m containing egfr mutants
WO2015038417A1 (en) * 2013-09-10 2015-03-19 Asana Biosciences, Llc Compounds for regulating fak and/or src pathways
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
WO2015073267A1 (en) * 2013-11-15 2015-05-21 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
EP3080131B1 (en) 2013-12-10 2018-10-10 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
WO2015131080A1 (en) * 2014-02-28 2015-09-03 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
NO2721710T3 (https=) * 2014-08-21 2018-03-31
EP3262049B1 (en) 2015-02-27 2022-07-20 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
TW201718571A (zh) * 2015-06-24 2017-06-01 必治妥美雅史谷比公司 經雜芳基取代之胺基吡啶化合物
EP3848370B1 (en) 2016-10-14 2025-05-07 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof

Similar Documents

Publication Publication Date Title
JP2019535807A5 (https=)
IL271999B2 (en) Tyk2 inhibitors and uses thereof
AU2018265130B2 (en) Thienopyridines and benzothiophenes useful as IRAK4 inhibitors
HRP20200179T1 (hr) Spojevi heteroarila kao inhibitori irak i njihova uporaba
JP2019532930A5 (https=)
JP2016530297A5 (https=)
US9102686B2 (en) 5,6,7,8,9,10-hexahydro-6,10-epimino[1,2,4]triazolo[4,3-a]azocines as P2X7 modulators
RU2008130884A (ru) Гетероциклические ингибиторы янус-киназы 3
JP2009532475A5 (https=)
RU2019105719A (ru) Антагонисты tlr7/8 и их применение
JP2017536369A5 (https=)
JP2019530699A5 (https=)
JP2017537110A (ja) ヘテロ環式誘導体およびその使用
HRP20100032T1 (hr) Tiadiazolidinoni kao inhibitori gsk-3
JP2013515729A5 (https=)
JP2014512404A5 (https=)
CA2510534A1 (en) Compositions useful as inhibitors of protein kinases
JP2020511438A5 (https=)
JP2016540803A5 (https=)
RU2018104705A (ru) Производные пиримидина в качестве btk ингибиторов и их применение
JP2016028076A5 (https=)
JPWO2020081508A5 (https=)
CN102083809B (zh) 基于阻断TCR-Nck相互作用的免疫抑制物
US10766896B2 (en) Imidazo[4,5-c] ring compounds containing guanidine substituted benzamide groups
CN106478475B (zh) 增稠稳定剂、以及使用该增稠稳定剂的增稠稳定化组合物